Abbott Laboratories (ABT)

ABT (NYSE:Health Services) EQUITY
pos +0.00
Today's Range: 0.00 - 0.00 | ABT Avg Daily Volume: 4,783,200
Last Update: 05/21/15 - 4:01 PM EDT
Volume: 0
YTD Performance: 9.60%
Open: $0.00
Previous Close: $49.34
52 Week Range: $39.24 - $49.43
Oustanding Shares: 1,488,757,318
Market Cap: 73,157,534,607
6-Month Chart
TheStreet Ratings Grade for ABT
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 9 9 8
Moderate Buy 4 4 4 4
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.75 1.75 1.79
Latest Dividend: 0.24
Latest Dividend Yield: 1.95%
Dividend Ex-Date: 04/13/15
Price Earnings Ratio: 36.95
Price Earnings Comparisons:
ABT Sector Avg. S&P 500
36.95 17.80 27.02
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.92% 24.72% 59.65%
Revenue -7.30 -0.48 -0.19
Net Income -11.30 -0.64 -0.28
EPS -8.00 -0.50 -0.21
Earnings for ABT:
Revenue 20.25B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $0.50 $0.55 $2.16 $2.41
Number of Analysts 12 11 16 16
High Estimate $0.51 $0.57 $2.20 $2.47
Low Estimate $0.50 $0.51 $2.14 $2.35
Prior Year $0.54 $0.62 $2.28 $2.16
Growth Rate (Year over Year) -6.94% -11.00% -5.18% 11.65%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
You could throw darts at financials and health care and win. 
Apr 24, 2015 | 6:48 AM EDT
ABT - Abbott Laboratories Annual Shareholders Meeting - 10AM
And have we mentioned Greece?

Earnings Growth Boosts AbbVie Real Money Pro($)

Drug franchises are still going strong.
The logic of owning the pure play is attractive.
Jan 30, 2015 | 7:09 AM EST
ABT was upgraded from Neutral to Buy, Bank of America/Merrill Lynch said. $52 price target. Company can deliver strong revenue growth a...
Jan 13, 2015 | 7:18 AM EST
ABT was downgraded from Buy to Hold, Jefferies said. $50 price target. Valuation call, as the company lacks near-term visibility.  ...
It's worth looking at the dividend payers this time of year.

Merger Mania Benefits Mylan Real Money Pro($)

Whether it's acquiring or the acquired, Mylan is building shareholder value.
Oct 29, 2014 | 6:31 AM EDT
ABT was upgraded to Buy, Deutsche Bank said. $54 price target. Management has the company poised to deliver sustained growth. 

Columnist Conversations

$600 million to buy market on close.
Much of what I'm hearing lately is the market is boring, it's a snooze-fest and nowhere is there a profit to b...
The Emini S&P 500 (e-SPM) and crude oil are following the same path today -- to the upside. In fact, the a...
On the weekly chart you can see the stock has recently tested a number of support lines and the 40 week (200 d...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.